BACKGROUND: Mixed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproducible strategy for the induction of tolerance toward solid organs. Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chimerism leads to tolerance of antigenic vascularized composite allografts. METHODS: Stable mixed chimerism was established in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immunosuppression after dog leukocyte antigen-identical marrow transplantation. Vascularized composite allografts from marrow donors were performed after a median of 36 months (range, 4-54 months) after HCT. RESULTS: All marrow recipients maintained mixed donor-host hematopoietic chimerism and accepted vascularized composite allografts for periods ranging between 52 and 90 weeks; in turn, marrow donors rejected vascularized composite allografts from their respective marrow recipients within 18 to 29 days. Biopsies of muscle and skin of vascularized composite allografts from mixed chimeras showed few infiltrating cells compared with extensive infiltrates in biopsies of vascularized composite allografts from marrow donors. Elevated levels of CD3+ FoxP3+ T-regulatory cells were found in skin and muscle of vascularized composite allografts of mixed chimeras compared with normal tissues. In mixed chimeras, increased numbers of T-regulatory cells were found in draining compared with nondraining lymph nodes of vascularized composite allografts. CONCLUSIONS: These data suggest that nonmyeloablative HCT may form the basis for future clinical applications of solid organ transplantation and that T-regulatory cells may function toward maintenance of the vascularized composite allograft.
BACKGROUND: Mixed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproducible strategy for the induction of tolerance toward solid organs. Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chimerism leads to tolerance of antigenic vascularized composite allografts. METHODS: Stable mixed chimerism was established in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immunosuppression after dog leukocyte antigen-identical marrow transplantation. Vascularized composite allografts from marrow donors were performed after a median of 36 months (range, 4-54 months) after HCT. RESULTS: All marrow recipients maintained mixed donor-host hematopoietic chimerism and accepted vascularized composite allografts for periods ranging between 52 and 90 weeks; in turn, marrow donors rejected vascularized composite allografts from their respective marrow recipients within 18 to 29 days. Biopsies of muscle and skin of vascularized composite allografts from mixed chimeras showed few infiltrating cells compared with extensive infiltrates in biopsies of vascularized composite allografts from marrow donors. Elevated levels of CD3+ FoxP3+ T-regulatory cells were found in skin and muscle of vascularized composite allografts of mixed chimeras compared with normal tissues. In mixed chimeras, increased numbers of T-regulatory cells were found in draining compared with nondraining lymph nodes of vascularized composite allografts. CONCLUSIONS: These data suggest that nonmyeloablative HCT may form the basis for future clinical applications of solid organ transplantation and that T-regulatory cells may function toward maintenance of the vascularized composite allograft.
Authors: Y Fuchimoto; Z L Gleit; C A Huang; H Kitamura; M L Schwarze; M T Menard; K Mawulawde; J C Madsen; D H Sachs Journal: Transplantation Date: 2001-07-15 Impact factor: 4.939
Authors: M Y Yunusov; C Kuhr; G E Georges; G E Sale; M Spector; M Lesnikova; R Lee; M-T Little; M J Gass; K Weber; A Joslyn; R Storb; R A Nash Journal: Transplant Proc Date: 2002-12 Impact factor: 1.066
Authors: Christian Junghanss; Alessandra Takatu; Marie-Terese Little; J Maciej Zaucha; Eustacia Zellmer; Murad Yunusov; George Sale; George E Georges; Rainer Storb Journal: Transplantation Date: 2003-02-15 Impact factor: 4.939
Authors: Christian S Kuhr; Margaret D Allen; Christian Junghanss; Jan M Zaucha; Christopher L Marsh; Murad Yunusov; Eustacia Zellme; Marie-Térèse Little; Beverly Torok-Storb; Rainer Storb Journal: Transplantation Date: 2002-05-15 Impact factor: 4.939
Authors: David W Mathes; Mark A Randolph; Mario G Solari; Jamal A Nazzal; G Petur Nielsen; J Scott Arn; David H Sachs; W P Andrew Lee Journal: Transplantation Date: 2003-01-15 Impact factor: 4.939
Authors: Zuhaib Ibrahim; Damon S Cooney; Jaimie T Shores; Justin M Sacks; Eric G Wimmers; Steven C Bonawitz; Chad Gordon; Dawn Ruben; Stefan Schneeberger; W P Andrew Lee; Gerald Brandacher Journal: J Vis Exp Date: 2013-10-14 Impact factor: 1.355
Authors: D A Leonard; J M Kurtz; C Mallard; A Albritton; R Duran-Struuck; E A Farkash; R Crepeau; A Matar; B M Horner; M A Randolph; D H Sachs; C A Huang; C L Cetrulo Journal: Am J Transplant Date: 2014-01-09 Impact factor: 8.086
Authors: Mohammed Al-Rakan; Jaimie T Shores; Steve Bonawitz; Gabriel Santiago; Joani M Christensen; Gerald Grant; Ryan J Murphy; Ehsan Basafa; Mehran Armand; Pete Otovic; Sue Eller; Gerald Brandacher; Chad R Gordon Journal: J Craniofac Surg Date: 2014-11 Impact factor: 1.046
Authors: Jeff Chang; Scott S Graves; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb; David Woodbridge Mathes Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: J Rodrigo Diaz-Siso; Ericka M Bueno; Geoffroy C Sisk; Francisco M Marty; Bohdan Pomahac; Stefan G Tullius Journal: Clin Transplant Date: 2013-04-14 Impact factor: 2.863
Authors: David W Mathes; Jeff Chang; Billanna Hwang; Scott S Graves; Barry E Storer; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb Journal: Transplantation Date: 2014-07-27 Impact factor: 4.939